CSL shares dip below $300 as it confirms M&A talks
On Friday, the stock fell $7.63 to $297.69 each – their lowest close since late October. The Swiss drugmaker’s shares shot up more than 20 per cent on the Swiss Stock Exchange overnight forcing Vifor to issue a statement telling investors “it systematically reviews options that can strengthen its market position and/or accelerate the growth of the company both organically and through partnerships and acquisitions”.